CIK 0001875558
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Nuvectis Pharma, Inc.
Sign in to watch- Ticker
- NVCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 862405608
- Phone
- +1 360-837-7232
- Business address
- 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
- 4 Open-market buy Chairman & CEO bought 2,000 shares at $6.40 ($12,800)
- 4 Open-market buy Chief Science & Business Off bought 500 shares at $6.29 ($3,145)
- 4 Open-market buy Chief Dev. & Ops. Officer bought 1,113 shares at $6.32 ($7,034)
- 4 Open-market buy Chairman & CEO bought 5,000 shares at $10.29 ($51,450)
- 4 Grant or award Chief Science & Business Off acquired 130,000 shares (grant or award)
- 4 Grant or award Chief Dev. & Ops. Officer acquired 130,000 shares (grant or award)
- 4 Open-market buy Chairman & CEO bought 640 shares at $11.08 ($7,091)
- 4 Open-market buy Chairman & CEO bought 1,080 shares at an average $11.21 ($12,105)
- 4 Open-market buy Chairman & CEO bought 3,220 shares at an average $11.01 ($35,455)
- 4 Open-market buy Chairman & CEO bought 350 shares at an average $14.61 ($5,112)
- 4 Open-market buy Chairman & CEO bought 300 shares at an average $14.73 ($4,418)
- 4 Open-market buy 10% owner bought 860 shares at $13.88 ($11,937)
- 4 Open-market buy 10% owner bought 2,584 shares at $13.91 ($35,943)
- 4 Open-market buy 10% owner bought 1,556 shares at $13.98 ($21,753)
- 4 Open-market buy 10% owner bought 10,000 shares at $13.97 ($139,700)
- 4 Open-market buy Chairman & CEO bought 335 shares at an average $14.92 ($4,998)
- 4 Open-market buy 10% owner bought 8,238 shares at an average $14.47 ($119,224)
- 4 Open-market buy 10% owner bought 8,000 shares at $14.84 ($118,720)
- 4 Open-market buy Chairman & CEO bought 200 shares at $14.33 ($2,866)
- 4 Open-market buy 10% owner bought 9,149 shares at $14.84 ($135,771)
Page 3 of 7 · 139 filings